Progression to cancer in patients with confirmed dysplasia compared to dysplasia downgraded to non-dysplastic metaplasia in Barrett’s esophagus: a retrospective cohort study in Sweden

Background/Aims This study aimed to clarify the risk of progression in patients with non-dysplastic Barrett’s esophagus (NDBE) and patients with confirmed low-grade dysplasia (LGD) and indefinite for dysplasia (IND) after an expert pathologist review of patients with BE with suspected dysplasia in a...

Full description

Saved in:
Bibliographic Details
Main Authors: Peter Elbe, Åke Öst, Lennart Mellbom, Anders Thorell, Bengt Håkanson, Fredrik Klevebro, Mats Lindblad
Format: Article
Language:English
Published: Korean Society of Gastrointestinal Endoscopy 2024-11-01
Series:Clinical Endoscopy
Subjects:
Online Access:http://www.e-ce.org/upload/pdf/ce-2023-313.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846142600279490560
author Peter Elbe
Åke Öst
Lennart Mellbom
Anders Thorell
Bengt Håkanson
Fredrik Klevebro
Mats Lindblad
author_facet Peter Elbe
Åke Öst
Lennart Mellbom
Anders Thorell
Bengt Håkanson
Fredrik Klevebro
Mats Lindblad
author_sort Peter Elbe
collection DOAJ
description Background/Aims This study aimed to clarify the risk of progression in patients with non-dysplastic Barrett’s esophagus (NDBE) and patients with confirmed low-grade dysplasia (LGD) and indefinite for dysplasia (IND) after an expert pathologist review of patients with BE with suspected dysplasia in a prospective cohort. Methods Patients with Barrett’s esophagus diagnosed with dysplasia at Ersta Hospital in Stockholm from 1998 to 2012 were included. The first dysplastic specimen in all patients was re-evaluated by two expert pathologists and classified as NDBE, LGD, IND, or cancer, including high-grade dysplasia. The incidence rates (IRs) and IR ratios were calculated with 95% confidence intervals. Results Of 423 patients with Barrett’s esophagus with dysplasia, 266 (62.9%) were re-classified as NDBE, 83 (19.6%) had LGD, 71 (16.8%) had IND, and 3 (0.7%) patients had cancer. During the follow-up, 34 (8%) patients developed cancer, most of them within five years, while others progressed after up to 25 years of surveillance. IRs for cancer among patients with NDBE was 0.41%/year compared to 1.84%/year for LGD (p<0.001) and 1.43%/year for IND (p=0.008). Conclusions Long-term risk of progression to cancer did not differ between patients with confirmed LGD and IND. These findings suggest that patients with IND should undergo similar management as patients with LGD.
format Article
id doaj-art-1ea3bd7d642442a5b55a3b1ba80eb31f
institution Kabale University
issn 2234-2400
2234-2443
language English
publishDate 2024-11-01
publisher Korean Society of Gastrointestinal Endoscopy
record_format Article
series Clinical Endoscopy
spelling doaj-art-1ea3bd7d642442a5b55a3b1ba80eb31f2024-12-03T07:42:10ZengKorean Society of Gastrointestinal EndoscopyClinical Endoscopy2234-24002234-24432024-11-0157676877410.5946/ce.2023.3137951Progression to cancer in patients with confirmed dysplasia compared to dysplasia downgraded to non-dysplastic metaplasia in Barrett’s esophagus: a retrospective cohort study in SwedenPeter Elbe0Åke Öst1Lennart Mellbom2Anders Thorell3Bengt Håkanson4Fredrik Klevebro5Mats Lindblad6 Department of Upper Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden Synlab AB Täby, Stockholm, Sweden Deceased, formerly at the Department of Pathology Karlskrona Hospital, Karlskrona, Sweden Department of Clinical Sciences, Danderyds Hospital, Karolinska Institutet and Department of Surgery, Ersta Hospital, Stockholm, Sweden Department of Clinical Sciences, Danderyds Hospital, Karolinska Institutet and Department of Surgery, Ersta Hospital, Stockholm, Sweden Department of Upper Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden Department of Upper Digestive Diseases, Karolinska University Hospital, Stockholm, SwedenBackground/Aims This study aimed to clarify the risk of progression in patients with non-dysplastic Barrett’s esophagus (NDBE) and patients with confirmed low-grade dysplasia (LGD) and indefinite for dysplasia (IND) after an expert pathologist review of patients with BE with suspected dysplasia in a prospective cohort. Methods Patients with Barrett’s esophagus diagnosed with dysplasia at Ersta Hospital in Stockholm from 1998 to 2012 were included. The first dysplastic specimen in all patients was re-evaluated by two expert pathologists and classified as NDBE, LGD, IND, or cancer, including high-grade dysplasia. The incidence rates (IRs) and IR ratios were calculated with 95% confidence intervals. Results Of 423 patients with Barrett’s esophagus with dysplasia, 266 (62.9%) were re-classified as NDBE, 83 (19.6%) had LGD, 71 (16.8%) had IND, and 3 (0.7%) patients had cancer. During the follow-up, 34 (8%) patients developed cancer, most of them within five years, while others progressed after up to 25 years of surveillance. IRs for cancer among patients with NDBE was 0.41%/year compared to 1.84%/year for LGD (p<0.001) and 1.43%/year for IND (p=0.008). Conclusions Long-term risk of progression to cancer did not differ between patients with confirmed LGD and IND. These findings suggest that patients with IND should undergo similar management as patients with LGD.http://www.e-ce.org/upload/pdf/ce-2023-313.pdfadenocarcinomabarrett esophagussurveillance
spellingShingle Peter Elbe
Åke Öst
Lennart Mellbom
Anders Thorell
Bengt Håkanson
Fredrik Klevebro
Mats Lindblad
Progression to cancer in patients with confirmed dysplasia compared to dysplasia downgraded to non-dysplastic metaplasia in Barrett’s esophagus: a retrospective cohort study in Sweden
Clinical Endoscopy
adenocarcinoma
barrett esophagus
surveillance
title Progression to cancer in patients with confirmed dysplasia compared to dysplasia downgraded to non-dysplastic metaplasia in Barrett’s esophagus: a retrospective cohort study in Sweden
title_full Progression to cancer in patients with confirmed dysplasia compared to dysplasia downgraded to non-dysplastic metaplasia in Barrett’s esophagus: a retrospective cohort study in Sweden
title_fullStr Progression to cancer in patients with confirmed dysplasia compared to dysplasia downgraded to non-dysplastic metaplasia in Barrett’s esophagus: a retrospective cohort study in Sweden
title_full_unstemmed Progression to cancer in patients with confirmed dysplasia compared to dysplasia downgraded to non-dysplastic metaplasia in Barrett’s esophagus: a retrospective cohort study in Sweden
title_short Progression to cancer in patients with confirmed dysplasia compared to dysplasia downgraded to non-dysplastic metaplasia in Barrett’s esophagus: a retrospective cohort study in Sweden
title_sort progression to cancer in patients with confirmed dysplasia compared to dysplasia downgraded to non dysplastic metaplasia in barrett s esophagus a retrospective cohort study in sweden
topic adenocarcinoma
barrett esophagus
surveillance
url http://www.e-ce.org/upload/pdf/ce-2023-313.pdf
work_keys_str_mv AT peterelbe progressiontocancerinpatientswithconfirmeddysplasiacomparedtodysplasiadowngradedtonondysplasticmetaplasiainbarrettsesophagusaretrospectivecohortstudyinsweden
AT akeost progressiontocancerinpatientswithconfirmeddysplasiacomparedtodysplasiadowngradedtonondysplasticmetaplasiainbarrettsesophagusaretrospectivecohortstudyinsweden
AT lennartmellbom progressiontocancerinpatientswithconfirmeddysplasiacomparedtodysplasiadowngradedtonondysplasticmetaplasiainbarrettsesophagusaretrospectivecohortstudyinsweden
AT andersthorell progressiontocancerinpatientswithconfirmeddysplasiacomparedtodysplasiadowngradedtonondysplasticmetaplasiainbarrettsesophagusaretrospectivecohortstudyinsweden
AT bengthakanson progressiontocancerinpatientswithconfirmeddysplasiacomparedtodysplasiadowngradedtonondysplasticmetaplasiainbarrettsesophagusaretrospectivecohortstudyinsweden
AT fredrikklevebro progressiontocancerinpatientswithconfirmeddysplasiacomparedtodysplasiadowngradedtonondysplasticmetaplasiainbarrettsesophagusaretrospectivecohortstudyinsweden
AT matslindblad progressiontocancerinpatientswithconfirmeddysplasiacomparedtodysplasiadowngradedtonondysplasticmetaplasiainbarrettsesophagusaretrospectivecohortstudyinsweden